Evidence map›Paper›PMID 31125364›Full record

ArticlePloS one2019

Delivery of different genes into pre- and post-synaptic neocortical interneurons connected by GABAergic synapses.

Aarti Nagayach, Anshuman Singh, Angel L De Blas, Alfred I Geller

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Recombinant Antibodies in Basic Neuroscience Research.Current protocols in neuroscience · 2020
    Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Aarti NagayachDepartment of Ophthalmology, Louisiana State University Health Sciences Center, New Orleans, Louisiana, United States of America.
Anshuman SinghDepartment of Ophthalmology, Louisiana State University Health Sciences Center, New Orleans, Louisiana, United States of America.
Angel L De BlasDepartment of Physiology and Neurobiology, University of Connecticut, Storrs, Connecticut, United States of America.
Alfred I GellerDepartment of Ophthalmology, Louisiana State University Health Sciences Center, New Orleans, Louisiana, United States of America.ORCID 0000-0001-6313-5250
Louisiana State University Health Sciences Center New Orleans · USUniversity of Connecticut · US

Funding

Targeted gene transfer across specific synapse typesR01NS086960 · NINDS · LSU HEALTH SCIENCES CENTER · PI GELLER, ALFRED I. · 2014 to 2017
$1.4M
NINDS NIH HHS R01 NS086960
6 · The paper itself

Abstract

Local neocortical circuits play critical roles in information processing, including synaptic plasticity, circuit physiology, and learning, and GABAergic inhibitory interneurons have key roles in these circuits. Moreover, specific neurological disorders, including schizophrenia and autism, are associated with deficits in GABAergic transmission in these circuits. GABAergic synapses represent a small fraction of neocortical synapses, and are embedded in complex local circuits that contain many neuron and synapse types. Thus, it is challenging to study the physiological roles of GABAergic inhibitory interneurons and their synapses, and to develop treatments for the specific disorders caused by dysfunction at these GABAergic synapses. To these ends, we report a novel technology that can deliver different genes into pre- and post-synaptic neocortical interneurons connected by a GABAergic synapse: First, standard gene transfer into the presynaptic neurons delivers a synthetic peptide neurotransmitter, containing three domains, a dense core vesicle sorting domain, a GABAA receptor-binding domain, a single-chain variable fragment anti-GABAA ß2 or ß3, and the His tag. Second, upon release, this synthetic peptide neurotransmitter binds to GABAA receptors on the postsynaptic neurons. Third, as the synthetic peptide neurotransmitter contains the His tag, antibody-mediated, targeted gene transfer using anti-His tag antibodies is selective for these neurons. We established this technology by expressing the synthetic peptide neurotransmitter in GABAergic neurons in the middle layers of postrhinal cortex, and the delivering the postsynaptic vector into connected GABAergic neurons in the upper neocortical layers. Targeted gene transfer was 61% specific for the connected neurons, but untargeted gene transfer was only 21% specific for these neurons. This technology may support studies on the roles of GABAergic inhibitory interneurons in circuit physiology and learning, and support gene therapy treatments for specific disorders associated with deficits at GABAergic synapses.

Indexed as

AnimalsGABAergic NeuronsGenetic VectorsGene Transfer TechniquesInterneuronsMiceNeocortexNeurotransmitter AgentsPeptide FragmentsReceptors, GABA-AReceptors, GABA-BSingle-Chain AntibodiesSynapsesNeurotransmitter AgentsPeptide FragmentsReceptors, GABA-AReceptors, GABA-BSingle-Chain Antibodies

Identifiers

PMID31125364
PMCPMC6534327
OpenAlexW2944843020

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.